Addendum
Ivacaftor (cystic fibrosis) - Addendum to Commissions G20-18, G20-20, A20-77, A20-83
Report documents
-
Addendum
Secukinumab (psoriatic arthritis) - Addendum to Commission A20-80
Additional information
Federal Joint Committee (G-BA)
18.02.2021: A G-BA decision was published.
Project details
- Project no.
- G21-03
- Commission
- Commission awarded on 12.01.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor, cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed